Dextran-based platform for targeted delivery of a payload

Aqueous-dispersible nanoparticles with a hydrophilic core and amphiphilic shell, formed by dextran and cationic lipids, address the inefficiencies of current carriers by achieving high transfection efficiency and specificity for targeted cell delivery, facilitating treatments for cancer and autoimmune diseases.

WO2026233901A1PCT designated stage Publication Date: 2026-11-12DANMARKS TEKNISKE UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2026/062750
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-05
Filing Date
2026-05-04
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current nanoparticle carriers for delivering immunotherapeutic agents, such as synthetic lipid or polymeric nanoparticles, face challenges including low transfection efficiency, lack of specificity, toxicity, and high production costs, limiting their application in treating diseases like cancer and autoimmune disorders.

Method used

Development of an aqueous-dispersible nanoparticle composed of a hydrophilic core and a shell made of an amphiphilic copolymer, formed by a hydrophobic dextran polymer covalently linked to a hydrophilic polymer, with a targeting agent, which is synthesized through a water-in-oil-in-water emulsification process, allowing for efficient and specific delivery of therapeutic agents to target cells.

Benefits of technology

The nanoparticles exhibit high transfection efficiency, specificity, and stability, enabling effective delivery of nucleic acids, proteins, and small molecules to hard-to-transfect cell lines, including primary T cells, with potential applications in treating cancer, autoimmune diseases, and cardiovascular diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure EP2026062750_12112026_PF_FP_ABST
    Figure EP2026062750_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The invention relates to a nanoparticle carrier for cell-targeted delivery of one or more therapeutic agent(s) to a mammalian cell, wherein the agent is capable of modulating the properties of a target cell, such as modulating its genome and / or inducing the expression of one or more native or non-native genes. The nanoparticles are water- dispersible and are composed of a shell comprising dextran copolymers that are capable of encapsulating a cargo of therapeutic agents, as well as a targeting molecule conjugated to the nanoparticle surface that allows cell-specific and intracellular delivery of the cargo to a target mammalian cell.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] P3318PC00

[0002] TITLE: Dextran-based platform for targeted delivery of a payload

[0003] FIELD OF THE INVENTION

[0004] The invention relates to a nanoparticle carrier for cell-targeted delivery of one or more therapeutic agent(s) to a mammalian cell and / or tissue, wherein the agent is capable of modulating the properties of a target cell, such as modulating its genome and / or expression of one or more native or non-native genes. The nanoparticles are water-dispersible and are composed of a shell comprising hydrophobic dextran polymer covalently linked to a hydrophilic polymer that are capable of encapsulating a cargo of therapeutic agents, as well as conjugating a targeting moiety associated to the nanoparticle surface that allows cell- and / or tissue-specific and intracellular delivery of the cargo to a target mammalian cell.

[0005] BACKGROUND OF THE INVENTION

[0006] Modulation of immune cells through activation, inhibition, or modification to alter their properties has become a high-demand class of therapy, called immunotherapeutics. Since T cells play an essential role in the adaptive immune system, advanced gene transfer and genome-editing technologies have been applied to engineer T cells to develop various cellular therapies, such as chimeric antigen receptor (CAR)-T cell therapy, T-cell receptor (TCR) T-cell therapy or use of different targeting receptors in T cells. A few CAR T-cell therapies have been approved for leukemia and lymphoma, however, current CAR T-cell production requires a demanding and logistically challenging process to extract T-cells from a patient, ex vivo transfer of the CAR gene into the T-cells, and to expand and reinfuse the CAR T-cells into the patient. Consequently, the therapy is highly complex, time-consuming and hugely expensive, and far from being readily applicable to the growing number of cancer patients. Additionally, it is not a treatment option for patients with highly malignant cancers or with very low T cell counts. Recently, nanomedicine such as synthetic lipid or polymeric nanoparticles have been developed to improve CAR T-cell production by delivering genes to transfect T-cells in vivo. However, these nanoparticles are struggling to meet clinical expectations due to poor therapeutic benefits. Deficiencies such as low transfection efficiency, lack of specificity, toxicity and high production cost have largely limited their usage.

[0007] Since an effective carrier for delivering immunotherapeutic agents would open the door to the short- and long-term treatment of a wide range of diseases, such as cardiovascular diseases, autoimmune diseases, and cancer, there remains an unmet need to provide improved nanoparticle drug carriers, in particular for nucleic acid-based therapeutic agents.P3318PC00

[0008] The present invention satisfies this unmet need.

[0009] SUMMARY OF THE INVENTION

[0010] In a first embodiment, the invention provides an aqueous-dispersible nanoparticle for encapsulating and delivering one or more molecules or therapeutic agent(s) to a cell, wherein the nanoparticle comprises:

[0011] (a) a hydrophilic core comprising said one of more molecules or therapeutic agents; and

[0012] (b) a shell comprising molecules of an amphiphilic copolymer and a cationic lipid, wherein the nanoparticle is formed by water-in-oil-in-water emulsification, and wherein the copolymer is composed of a hydrophobic dextran polymer covalently linked to a hydrophilic polymer, wherein a polar head group of said cationic lipid is orientated towards the core, and a hydrophilic portion of said copolymer is orientated towards the exterior surface of the nanoparticle,

[0013] wherein the nanoparticle further comprises a targeting agent linked to the hydrophilic portion of said amphiphilic copolymer.

[0014] Preferably the copolymer is composed of an acetalated dextran polymer conjugated to a hydrophilic PEG polymer.

[0015] In a second embodiment, the invention provides method for producing a population of nanoparticles according to the first embodiment comprising:

[0016] (a) providing one or more aqueous solutions of one or more molecules or therapeutic agent(s) and providing a non-polar solution comprising an amphiphilic copolymer according to the first embodiment and a cationic lipid;

[0017] (b) mixing the aqueous solution(s) and the non-polar solution of (a) to form a water-in-oil emulsion;

[0018] (c) mixing an aqueous solution of a water-soluble synthetic polymer with the water-in-oil emulsion of (b) to form a water-in-oil-in-water emulsion;

[0019] (d) optionally, mixing a further aqueous solution of a water-soluble synthetic polymer with said water-in-oil-in-water emulsion of (c) and

[0020] (e) evaporating the non-polar solvent from the water-in-oil-in-water emulsion of (d) to provide an aqueous solution of nanoparticles;

[0021] andP3318PC00

[0022] (f) linking said nanoparticles of (e) with a cell-specific targeting agent;

[0023] wherein the copolymer is composed of a hydrophobic dextran polymer covalently linked to a hydrophilic polymer,

[0024] wherein a polar head group of said cationic lipid is orientated towards a hydrophilic core of the nanoparticle, and a hydrophilic portion of said copolymer is orientated towards the exterior surface of the nanoparticle, and

[0025] wherein said linking in step (f) comprises conjugating said targeting agent to a hydrophilic portion of said amphiphilic copolymer.

[0026] In a third embodiment, the invention provides a pharmaceutical composition for use as a medicament, comprising a population of the nanoparticles according to the first embodiment, wherein the hydrophilic core comprises one of more therapeutic agents. In a fourth embodiment, the invention provides a method for in vivo treatment of a subject in need thereof with a composition comprising a population of the nanoparticles according to the first embodiment, wherein the hydrophilic core comprises one of more therapeutic agents.

[0027] In a fifth embodiment, the invention provides a method of transfecting a mammalian cell ex vivo or in vitro with a population of the nanoparticles according to the first embodiment, comprising the step of contacting one or more mammalian cells (i.e. target cells such target mammalian immune cells) with the population of the nanoparticles of the first embodiment, whereby the one or more molecules or therapeutic agent(s) encapsulated by the nanoparticles are delivered to the one or more mammalian cells. The method may include the step of infusing the one or more mammalian cells contacted with said nanoparticles into a patient in need thereof.

[0028] DESCRIPTION OF THE INVENTION

[0029] Brief description of the figures:

[0030] Figure 1. A: Schematic of synthesis of an Azido-PEG-acetalatedDextran di-block polymer, showing amination of dextran by treatment with sodium cyanoborohydride and l-[(Dimethylamino)(morpholino)methylene]-lH-[l,2,3]triazolo[4,5-b]pyridine-l-ium 3-oxide hexafluorophosphate (HDMA) to form aminated dextran followed by the use of Azido-PEG-NHS to selectively couple an Azido-PEG molecule to the primary amine of the aminated dextran; and finally acetalation of the dextran block by means of pyridinium-p-toluene sulfonate and 2-methoxypropene.

[0031] B: Schematic of synthesis of a modified Azido-PEG-acetalated Dextran di-block polymer comprising a cleavable linker that covalently links the dextran portion to the azido-PEGP3318PC00

[0032] portion of the di-block. As shown, the linker is inserted using MC-Val-Cit-PAB-Gly-NHS ester, where the NHS reacts with the -amine group on the dextran, while the maleimide bonds to -SH PEG-N3.

[0033] C: Schematic of synthesis of an Azido-PEG-acetalated-dextran di-block polymer, showing amination of dextran by treatment with sodium cyanoborohydride and hexamethylene diamine (HMDA) to form aminated dextran followed by the use of Azido-PEG-NHS to selectively couple an Azido-PEG molecule to the primary amine of the aminated dextran; and finally acetalation of the dextran block by means of pyridinium-p-toluene sulfonate (PPTS) and 2-methoxypropene.

[0034] D: Schematic of synthesis of a modified Azido-PEG- acetalated-Dextran di-block polymer comprising a cleavable linker that covalently links the dextran portion to the azido-PEG portion of the di-block polymer. As shown, the linker is inserted using MC-Val-Cit-PAB-Gly-NHS ester, where the NHS reacts with the -amine group on the dextran, while the maleimide bonds to -SH PEG-N3.

[0035] E: Schematic of synthesis of an Azido-PEG-acetalated-dextran di-block polymer (compound 8C), showing amination of dextran by treatment with 2-(Aminoxy) ethylamine dihydrochloride to form aminated dextran followed by acetylation of the dextran block by the use of pyridinium toluenesulfonate and 2-methoxypropene. Finally, Azido-PEG5k-NHS was added.

[0036] F: Schematic of synthesis of an azido-PEG-acetalated dextran polymer (compound 12C), showing azididation of dextran by treatment with 2-(2-(2-azidoethoxy)ethoxy)ethyl 1H-imidazole-l-carboxylate to form azidated dextran followed by acetalation of the dextran by the use of pyridinium toluenesulfonate and 2-methoxy propene.

[0037] Figure 2. Cartoon showing component molecules of the nanoparticles and their step-wise assembly.

[0038] Figure 3. A: Cartoon showing the preparation of cargo-loaded nanoparticles composed of a shell of amphiphilic azido-PEG-acetalated dextran di-block copolymer and cationic DC-cholesterol using a double emulsion method.

[0039] B: Flow diagram showing the preparation of cargo-loaded nanoparticles using a double emulsion method. Optional steps are indicated by stippled line boxes.

[0040] Figure 4. Cartoon showing the structure of cargo-loaded amphiphilic dextran di-block co-polymer: cationic lipid nanoparticles and the conjugation with DBCO-modified antibody by using conjugation chemistry (e.g. click chemistry).P3318PC00

[0041] Figure 5 A: Images of GFP expression by in vitro transfected mammalian CD3 knockdown and wild type (WT) Jurkat T cells using CD3-targeted amphiphilic dextran di-block co-polymer: cationic lipid nanoparticles loaded with a cargo of GFP mRNA following incubation in cell culture medium for 24 h.

[0042] B: A histogram showing the frequency of GFP-expressing T cells in a population of wild-type or CD3 knockout (CD3 KO) Jurkat cells following in vitro transfection with increasing amounts of CD3-targeted amphiphilic dextran di-block co-polymer: cationic lipid nanoparticles loaded with a cargo of GFP mRNA .

[0043] Figure 6. Human purified CD3+ T cells (Figure 6A to C) or total PBMCs (Fig 6D) were incubated in vitro for 24 hours with human CD3-targeting amphiphilic dextran di-block co-polymer: cationic lipid nanoparticles loaded with a CD19-CAR mRNA-cargo.

[0044] A: is an image demonstrating surface expression of the CD19 CAR construct on CD3+ T cells, analyzed by immunofluorescence microscopy. B: and C: further quantify the surface expression of the CD19-CAR on CD3+ T cells, that is depicted as the frequency of CAR+ mCherry+ (a reporter co-encoded on the CAR mRNA construct) CD3+ T cells following incubation of purified T cells with CD3-targeting CD19 CAR-ligand-loaded nanoparticles, without or without a step of preincubation of the nanoparticles (NP) in human serum (+ human serum, HS) for 12 hours. D: demonstrates selective targeting of nanoparticles (NP) to CD3+ T cells only, when CD3-targeting nanoparticles were administered to a PBMC sample composed of a variety of immune cell types.

[0045] Figure 7. Cartoon illustrating in vivo transfection of T cells using amphiphilic dextran di-block co-polymer: cationic lipid nanoparticles of the invention.

[0046] Figure 8. A: Flow cytometry analysis of mCherry expression by Jurkat cells following in vitro transfection with nanoparticles comprising a cargo of mCherry mRNA and conjugated with anti-CD3 antibody, wherein the nanoparticles were prepared according to example 8.2. B: Flow cytometry analysis performed on Jurkat cells transfected with nanoparticles as in (A), but wherein the nanoparticles were prepared according to examples 8.4. C: Flow cytometry analysis performed on Jurkat cells transfected with nanoparticles as in (A), but wherein the nanoparticles were prepared according to examples 8.6. Y axis shows mean fluorescence intensity units of FSC-H and X axis shows mean fluorescence intensity unit of PE-CF594-A. The results of the flow cytometry analysis shown in the left- and right-hand panels of each of A, B and C were based on duplicate transfection experiments.

[0047] Figure 9. Bioluminescence images of dissected organs of mice following in vivo transfection with nanoparticles comprising a cargo of luciferase mRNA, wherein theP3318PC00

[0048] nanoparticles were prepared according to examples 8.7. The scale to the right shows bioluminescence intensity (e- / S).

[0049] Figure 10. Flow cytometry analysis of GFP expression by Jurkat cells following in vitro transfection with nanoparticles comprising a cargo of GFP mRNA and conjugated with anti-CD3 antibody, wherein the nanoparticles were prepared according to example 11.2 and 11.3. The Y axis measures Side Scatter Area (SSC-A), and the X axis measures Near-Infrared (NIR) fluorescence or GFP fluorescence.

[0050] Abbreviations, terms and definitions:

[0051] Acdextran: is acetalated dextran.

[0052] Azido-PEG- acetalated dextran copolymer: is composed of an azido-PEG polymer covalently linked to an acetalated dextran polymer. The azido-PEG polymer may be covalently linked to the non-reducing end of an acetalated dextran polymer to form an azido-PEG-acetalated dextran di-block copolymer, or it may be covalently linked to a side group (e.g. OH group) of said acetalated dextran polymer or it may be linked to the reducing end of the acetalated dextran polymer.

[0053] Dextran polymer: in the context of the present invention, is a predominantly linear poly-a-d-glucoside having glycosidic bonds predominantly C-l C-6; having a molecular weight in the range of 1-100 kDa, such as from 2-80 kDa, such as from 3-50 kDa, such as from 5-40 kDa, such as from 7-15 or 8-13 kDa, such as from 15-30 kDa, or such as from 30-50 kDa. Dextran polymers having a molecular weight in the range of from 9-11 kDa, are obtainable from Leuconostoc mesenteroides.

[0054] Nanoparticle: as defined herein is a particle of matter that is between 10 and 500 nanometers in diameter, such as between 100 and 500 nanometers in diameter, as measured by the method described in Example 5.

[0055] Nanoparticle formed by w / o / w emulsion: is a nanoparticle comprising azido-PEG -acetalated dextran: cationic lipid copolymers that are obtainable by means of a double emulsion water / oil / water and evaporation procedure, as described in Example 2. Nanoparticles according to the invention comprise one of more cargo molecules that are encapsulated within the nanoparticles; encapsulation being obtainable by forming said nanoparticles from a mixture of azido-PEG- acetalated dextran: cationic lipid copolymers in combination with said cargo molecules by means of w / o / w emulsification.

[0056] Cargo molecule: in the context of the present invention, a cargo molecule is one that can be carried as a cargo by a nanoparticle of the invention, where the molecule is one that can be protected from the environment by virtue of encapsulation within theP3318PC00

[0057] nanoparticle. Furthermore, the cargo molecule is one that can both be encapsulated by the nanoparticle and subsequently released from the nanoparticle, without significant loss of its functional properties. When the cargo molecule is a therapeutic molecule, it may be selected from among a nucleic acid molecule, a protein, peptide or polypeptide molecule, a small molecule, and any combination thereof.

[0058] Conjugated: two entities or moieties are conjugated if they are stably linked by a chemical bond or linkage, such that each component retains some of its structure and at least part of its original functionality.

[0059] Cell-selective targeting ligand: ligand to any one of a cell receptor, an aptamer, a peptide, an antibody (such as a polyclonal or monoclonal antibody, a scFv and Fab fragment, a nanobody, and a mini-protein binder), that can facilitate the cell- and / or tissue-specific targeting of a nanoparticle comprising the ligand to its target immune cell.

[0060] DBCO: is dibenzocyclooctyne group (DBCO). DBCO can be used for copper-free click chemistry, where the DBCO group preferentially and spontaneously interacts with molecules containing azide groups (-N3).

[0061] DCM: is Dichloromethane. DCM can be used as a solvent.

[0062] GFP: is green fluorescent protein.

[0063] HDMA: is l-[(Dimethylamino)(morpholino)methylene]-lH-[l,2,3]triazolo[4,5-b]pyridine-l-ium 3-oxide hexafluorophosphate.

[0064] HMDA: is hexamethylene diamine, also known as 1,6-diamino-hexane.

[0065] Immune cell surface receptor ligand: is a ligand to a cell surface receptor of an immune cell, where the immune cell is a monocyte or a lymphocyte selected from among a T cell (e.g. CD4-, CD8-T cell; gamma-delta-T cell [y6-T cell]), B cell and NK cell, or a combination thereof.

[0066] NHS: is an N-hydroxysuccinimide (NHS) ester moiety / group, or a moiety comprising an N-hydroxysuccinimide moiety.

[0067] PBS: is Phosphate-buffered saline, a buffer solution (pH ~ 7.4).

[0068] PEG: is Polyethylene glycol or a moiety comprising a PEG.

[0069] PVA: is Polyvinyl alcohol, a water-soluble synthetic polymer having the idealized formula [CH2CH(OH)]n.P3318PC00

[0070] Target mammalian immune cell: includes a monocyte or a lymphocyte selected from among a T cell (e.g. CD4-, CD8-T cell; gamma-delta-T cell [y6-T cell]), B cell and NK cell, or a combination thereof; to which nanoparticles of the invention may be targeted by means of a cell-selective targeting agent.

[0071] w / o / w emulsion: is a water in oil in water double emulsion.

[0072] Acetalated: refers to a compound or moiety that has been chemically modified to include one or more acetal functional groups.

[0073] Detailed description of the invention:

[0074] I: In a first embodiment, the invention provides an aqueous-dispersible nanoparticle for encapsulating and delivering one or more therapeutic agent(s) to a cell, wherein the nanoparticle comprises:

[0075] (a) a hydrophilic core comprising one of more molecules or therapeutic agents;

[0076] (b) a shell comprising molecules of an amphiphilic copolymer and a cationic lipid, and (c) a targeting agent conjugated to a hydrophilic block of said dextran copolymer, wherein the nanoparticle is formed by w / o / w emulsification, and

[0077] wherein the copolymer is composed of a hydrophobic dextran polymer covalently linked to a hydrophilic polymer,

[0078] wherein a polar head group of said cationic lipid is orientated towards the core, and a hydrophilic portion of each dextran copolymer is orientated towards the exterior surface of the nanoparticle.

[0079] In one embodiment, the aqueous-dispersible nanoparticles comprise amphiphilic polymers, which comprise acetalated dextran polymers covalently linked to azido-PEG polymers. Each acetalated dextran polymer may be substituted at the non-reducing end or at the reducing end with an azido-PEG polymer. Alternatively, each acetalated dextran polymer may be covalently linked to an azido-PEG polymer through a side group (e.g. OH group) of said acetalated dextran polymer. Preferably, the azido-PEG-acetalated dextran copolymer has a linear block structure. The azido-PEG portions of the copolymers, having hydrophilic properties, are orientated towards the exterior surface of the nanoparticles, while the acetalated dextran portions, having hydrophobic properties, form the shell of the nanoparticles together with the non-polar tail of the cationic lipid molecules. Preferably, the azido-PEG-acetalated dextran copolymer is anP3318PC00

[0080] azido-PEG-acetalated dextran di-block copolymer that can be synthesized as described in example 1A and 1C (Figure 1A or figure 1C).

[0081] The dextran polymers are predominantly linear poly-a-d-glucosides having glycosidic bonds predominantly C-l C-6, and have a molecular weight in the range of 1-100 kDa, such as from 2-80 kDa, such as from 3-50 kDa, such as from 5-40 kDa, such as from 7-15 or 8-13 kDa, such as froml5-30 kDa, or such as from 30-50 kDa. In some embodiments, the dextran polymer has a molecular weight in the range of 8 - 12 kDa or 9-11 kDa, for example dextran obtainable from Leuconostoc mesenteroides.

[0082] The azido-PEG block comprises PEG, where the molecular weight of the PEG moiety is between 100 and 20000 Da, such as between 200 and 15000 Da, such as between 400 and 10000 Da, such as between 1000 and 7500 Da, such as between 2000 and 6000 da, such as about 5000.

[0083] The cationic lipid is preferably selected from among cholesteryl 3 -N-(dimethylaminoethyl)carbamate hydrochloride (DC-cholesterol); 1,2-di-O-octadecenyl-3-trimethylammonium-propane (DOTMA); 8-[(2-hydroxyethyl)[8-(nonyloxy)-8-oxooctyl]amino]-octanoic acid, 1-octylnonyl ester (lipidoid 5), l,2-dioleoyl-3-trimethylammonium-propane (18:1 TAP or DOTAP), and Nl,N16-didodecyl-4,7,13-tris(3-(dodecylamino)-3-oxopropyl)-4,7,10,13-tetraazahexadecanediamide. Preferably, the polar head groups of the lipid molecules are orientated towards the core of the nanoparticle, where their cationic charge facilitates, in particular, the encapsulation of cargo molecules (or domains or molecular groups thereof), having a net negative charge, such as nucleic acids.

[0084] Optionally the nanoparticle can further comprise molecules of an enzyme-responsive peptide, where the peptide is a substrate of the enzyme. The peptide can be incorporated into a linker for further conjugation into nanoparticles of the present invention. By way of example, an enzyme-responsive peptide can be a cathepsin-responsive peptide, such as Valine-Citrulline dipeptide, that is cleavable by cathepsin. The Val-Cit dipeptide can be formulated into a cleavable linker such as MC-Val-Cit-PAB-Gly-NHS ester, that comprises a maleimide group (MC), a valine-citrulline (Val-Cit) dipeptide, and a paraaminobenzyl (PAB) spacer ligated to a glycine- N-hydroxysuccinimide residue (glycine-NHS). NHS ester can react with the -amine group on the dextran, while the maleimide group which is highly reactive towards thiols can be used to connect to -SH-PEG-N3 (Figure IB or ID). The resulting modified amphiphilic azido-PEG-acetalated dextran copolymer, where the dextran portion is linked to the azido-PEG portion by a cleavable linker (i.e. using an MC-Val-Cit-PAB-Gly-NHS ester) can then be assembled with the cationic lipid using double emulsion to form a modified nanoparticle of the invention.P3318PC00

[0085] Preferably, the proteolytic cleavage of the dipeptide linker in nanoparticles comprising the modified amphiphilic azido-PEG-acetalated dextran copolymer (e.g. figure IB) would trigger an efficient release of the azido-PEG portion of the copolymer, and thereby lead to the disassembly of the nanoparticle and release of its cargo of therapeutic agent(s), for example in vivo following administration to a subject.

[0086] The cargo-loaded aqueous-dispersible nanoparticles are assembled from their component parts by w / o / w emulsification as exemplified in example 2.

[0087] The aqueous-dispersible nanoparticles comprise one or more cargo molecules disposed within the nanoparticles, wherein at least one of said cargo molecules is a molecule or a prophylactic- or therapeutic-agent. The one or more cargo molecules include nucleic acid molecule(s), peptide(s), polypeptide(s), small molecule(s), or any combination thereof.

[0088] When the cargo molecule is a nucleic acid molecule, it may be a deoxyribonucleic acid molecule including single-stranded DNA, double-stranded DNA, plasmid DNA, mini circle DNA and an oligodeoxynucleotide, or any combination thereof. Alternatively, the nucleic acid molecule may be a ribonucleic acid molecule or nucleoside-modified RIMA, including interfering RNA (RNAi), short hairpin RNA (shRNA), double-stranded RNA (dsRNA), RNA polymerase III transcribed RNA, messenger RNA (mRNA), and antisense ribonucleic acid molecule, guide RNA (gRNA), or any combination thereof.

[0089] When the nucleic acid molecule is nucleoside-modified RNA, for example by comprising pseudouridine in substitution for uridine, the nucleoside-modified RNA may be synthesized by T7 phage RNA polymerase.

[0090] When the RNA is mRNA, this may be obtained by in vitro transcription (IVT) of a DNA template. The RNA preferably has 5' and 3' UTRs whose length can be modified in order to achieve optimal translation efficiency following transfection and delivery of the transcribed RNA encapsulated within the nanoparticle. The 5TITR may comprise a Kozak sequence to enhance translation efficiency. In a preferred embodiment, the RNA has both a cap on the 5' end and a 3' poly(A) tail which determines ribosome binding, initiation of translation and stability mRNA in the cell. In one embodiment, the one or more cargo molecules comprise mRNA molecules encoding one or more therapeutic proteins.

[0091] The one or more cargo molecules may comprise at least the essential components of a CRISPR-Cas system that are required for gene editing or gene insertion, including a CRISPR-associated polypeptide (e.g., CRISPR-Cas9 or CRISPR-Casl2 endonucleases), a DNA template, and a guide RNA (gRNA), that together form a complex within the cell to which the nanoparticle is targeted. In one embodiment of the CRISPR-Cas system-P3318PC00

[0092] loaded nanoparticle, the gRNA is targeted to a specific nucleotide sequence in a gene in the genome of the target cell, where the DNA template is a repair template for editing the nucleotide sequence of the targeted gene, said editing including the insertion or substitution or deletion of one of more nucleotides. In another embodiment of the CRISPR-Cas system-loaded nanoparticle, the DNA template encodes a gene for insertion into the cell genome at a location targeted by the gRNA.

[0093] The nanoparticles of the present invention are capable of encapsulating both small and larger proteins, as exemplified by encapsulation of model proteins of 50 kDA or greater in size, such as the 52 kDa protein streptavidin.

[0094] When the one or more cargo molecules are polypeptides, they may be selected from among gene-editing systems (e.g. Crispr associated proteins), functional enzymes, and therapeutic proteins (e.g. Saporin). When the one or more cargo molecules are polypeptides, they may also be selected from a cytokine, an IL2 cytokine (16 kDa), IL2 / IL15.

[0095] When the cargo molecule is a small molecule, it may be selected from among a, a small molecule modulator of immune response / pathway, a check point inhibitor, and a TGF-beta signaling inhibitor.

[0096] The nanoparticles of the invention comprising one or more cargo molecules, including nucleic acid molecule(s), peptide(s), polypeptide(s), small molecule(s), or any combination thereof, are obtainable by combining the one or more cargo molecules with the nanoparticle polymers during w-o-w emulsification (as illustrated in example 2). The encapsulated cargo molecules are thereby protected against chemical and enzymatic degradation, such as following transfection into a mammalian cell.

[0097] The aqueous-dispersible nanoparticles according to the invention that are assembled from amphiphilic co-polymers comprising a hydrophilic azido-PEG block orientated towards their outer surface, and a hydrophobic dextran block orientated into their shell, combined with cationic lipids providing a positively charged inner lining to the shell, are surprisingly advantageous for several reasons: (1) the nanoparticles exhibit very high transfection efficiencies (such as 70-80% in a cancerous cell line), (2) the nanoparticles are capable of transfecting target cells with cargos of both smaller mRNAs (e.g. GFP mRNA) and protein-encoding plasmids (e.g GFP), as well larger mRNAs and DNA plasmids (e.g., plasmids encoding a CD19 CAR). When the nanoparticles further include a targeting agent that targets the nanoparticles to cells having a cognate ligand or cognate receptor; then the nanoparticles are surprisingly advantageous because (3) they are capable of transfecting cell lines that are known to be hard-to-transfect, such as Jurkat T cells and primary T cells; (4) they can be used to selectively transfect specificP3318PC00

[0098] cell types, such as transfection of only T cells in PBMC samples; and the loaded nanoparticles exhibit stability for in vitro and in vivo pharmaceutical use.

[0099] In one embodiment, the aqueous-dispersible nanoparticles are linked, or preferably conjugated, to a cell-specific targeting agent functionalized with a coupling agent. The coupling agent preferably comprises an alkyne dipolarophile, which is capable of reacting with a 1,3-dipole, such as an azide (in particular the azido group on the azido-PEG portion of the amphiphilic copolymers), to yield a stable triazole linkage. Examples of alkyne dipolarophiles are any strained cycloalkenes and cycloalkynes known to those of skill in the art, including, but not limited to, cyclooctynes, dibenzocyclooctynes (DBCO), monofluorinated cyclcooctynes, difluorinated cyclooctynes, and biarylazacyclooctynone (BARAC), (lR,8S,9s)- bicyclo[6.1.0]non-4-yn-9-ylmethanol (BCN). The conjugation between the 1,3-dipole, and the alkyne dipolarophile by means of a triazole linkage can be performed using Click Chemistry reactions.

[0100] In a preferred embodiment the alkyne dipolarophile moiety is provided by a water-soluble reagent such as a sulfonated moiety. In one embodiment, the water-soluble reagent is the sulfonated alkyne dipolarophile moiety, DBCO-Sulfo-NHS Ester. In one embodiment, the water-soluble reagent is DBCO-PEGn-NHS ester, wherein the PEG spacer can be from 1 - 6 units of its monomer, ethylene glycol (C2H6O2), more preferably 2 - 4 units, most preferably 4 units (for example DCBO-PEG4-NHS ester).

[0101] The cell-specific targeting agent can be a ligand such as any one of a ligand to a cell receptor, aptamer, peptide, antibody (polyclonal or monoclonal antibody, scFv and Fab fragment, and nanobody), and may be attached to the nanoparticle by means of a coupling agent. Preferably, the targeting ligand is functionalized with the above coupling agent, by chemical conjugation reactions known in the art. For example, when the ligand is an antibody (or fragment thereof) or nanobody, it can be functionalized with DCBO-PEG4-NHS ester, or preferably with DBCO-Sulfo-NHS Ester by conjugation with lysine residues in the antibody (or fragment thereof) or nanobody, as illustrated in example 3. The coupling agent used to conjugate the cell specific targeting ligand to the nanoparticle are both water-soluble and flexible, and in theory may facilitate greater steric mobility for interaction of the ligand with potential cell-specific targets on a cell.

[0102] II. In a second embodiment, the invention provides a method for preparing nanoparticles of the invention, where the nanoparticle comprises amphiphilic copolymers and a cationic lipid, wherein said co-polymers are azido-functionalized and conjugated to a targeting ligand, and wherein the nanoparticle further comprises one of more cargo molecules disposed therein. The method is further suitable for preparing all embodiments of said nanoparticles of the invention, as defined in section I.P3318PC00

[0103] The method, as further detailed in example 2, comprises the following steps;

[0104] (a) providing one or more aqueous solutions of the one or more molecules or therapeutic agent(s) and providing a non-polar solution comprising the amphiphilic copolymer and a cationic lipid;

[0105] (b) mixing the aqueous solution(s) and the non-polar solution of (a) to form a water-in-oil emulsion;

[0106] (c) mixing an aqueous solution of a water-soluble synthetic polymer (e.g. 3%PVA) with the water-in-oil emulsion of (b) to form a water-in-oil-in-water emulsion;

[0107] (d) optionally, mixing a further aqueous solution of water-soluble synthetic polymer (e.g. 0.3%PVA) with water-in-oil-in-water emulsion of (c) and

[0108] (e) evaporating the non-polar solvent from the water-in-oil-in-water emulsion of (e) to provide an aqueous solution of nanoparticles;

[0109] and optionally

[0110] (f) linking or conjugating said nanoparticles of (e) with a cell-specific targeting ligand, wherein the copolymer is composed of a hydrophobic dextran polymer covalently linked to a hydrophilic polymer (for example an amphiphilic azido-PEG-acetalated dextran copolymer), and

[0111] wherein a polar head group of said cationic lipid is orientated towards the core, and a hydrophilic portion of said copolymer is orientated towards the exterior surface of the nanoparticle.

[0112] In a preferred embodiment of step (a), the non-polar solution comprises the amphiphilic azido-PEG-acetalated dextran copolymer and the cationic lipid in a weight ratio of from 2:1 to 5:1, more preferably 2:1.

[0113] In a preferred embodiment of step (b) the aqueous solution(s) and the non-polar solution of (a) are mixed in a 1:5 ratio to form a water-in-oil emulsion;

[0114] In a preferred embodiment of step (c), the solution of water-soluble synthetic polymer (e.g. PVA; for example at least 2.5% PVA; or from 2.5% - 5% PVA; preferably 3%PVA) is mixed with the water-in-oil emulsion of (b) to form a water-in-oil-in-water emulsion. In a preferred embodiment of step (d), the solution of water-soluble synthetic polymer (e.g. PVA; for example in an amount of less than 2.5% PVA; or from 0% -2.5% PVA; preferably less than 1%, such as 0.3%PVA) is mixed with the water-in-oil emulsion of (c) to form a water-in-oil-in-water emulsion.

[0115] In a preferred embodiment the amphiphilic azido-PEG-acetalated dextran copolymer is an azido-PEG-acetalated dextran di-block copolymer (FigurelA or FigurelC).P3318PC00

[0116] In an alternative embodiment of step (a) the amphiphilic copolymer is a modified amphiphilic azido-PEG-acetalated dextran copolymer comprising an enzyme-responsive peptide (e.g. cleavable peptide) covalently linked between the dextran polymer block and the PEG polymer block, as described in section I, that may for example have the structure of figure IB or figure ID.

[0117] The nanoparticles according to the invention, and obtainable by the above method, are able to transfect target cells (e.g. immune cells), whereby their cargo molecules are effectively delivered to the target cells. When the cargo is a nucleic acid encoding a protein, then the encoded protein can be expressed in transfected cells. This is evidenced by the expression of proteins encoded by an mRNA cargo molecule as well as a plasmid, as demonstrated in examples 5.2, 6, 9, 10 and 11.

[0118] III. In a third embodiment, the invention provides a pharmaceutical composition for use as a medicament, comprising one or more nanoparticles according to the invention having a targeting ligand, wherein said one of more cargo molecules is a prophylactic or therapeutic active agent.

[0119] In one embodiment, the targeting ligand is an immune cell surface receptor ligand conjugated to the nanoparticle. The immune cell surface receptor ligand may be a ligand to a cell surface receptor of a target immune cell. The target cell may be a monocyte or a lymphocyte selected from among a T cell (e.g. CD4-, CD8-T cell; gamma-delta-T cell [y6-T cell]), B cell and NK cell. Cell surface receptors recognized by said ligands and suitable for cell-specific targeting include any receptor capable of facilitating internalization of the nanoparticle, such as a CD3, CD4 or CD8 receptor. Suitable ligands include antibodies, such as antibodies that bind to said receptors e.g. anti-CD3, anti-CD4, anti-CD8 antibodies.

[0120] The cell-specificity of nanoparticles according to the invention, is illustrated in example 4, where nanoparticles conjugated to anti-CD3 antibodies selectively transfected Jurkat cells having a CD3 cell surface receptor, while transfection rates for Jurkat cells lacking this receptor were greatly reduced. Transfection with the nanoparticles according to the invention is mediated by interaction between the targeting ligand on the nanoparticle and cell receptors accessible on the surface of the target cell, followed by internalization of the receptor and bound nanoparticle, a process that can be halted by treatment with e.g. Dasatinib.

[0121] At least one of the one or more cargo molecules encapsulated within said nanoparticles is an active agent having a prophylactic or therapeutic effect when administered to mammalian subject in need of treatment for a disease.P3318PC00

[0122] The active agent may have a prophylactic or therapeutic effect on a disease selected from among cancer, autoimmune disease, infectious disease, heart or vascular disease and immune-related disease.

[0123] Diseases treatable by administration of the nanoparticles of the invention include: Cancer (e.g. hematological malignancy): by way of example, a composition comprising nanoparticles of the invention, loaded with a cargo of'CD19 CAR' molecules for targeting lymphoblasts expressing CD19, can be used for treatment of a mammalian subject suffering from a hematological malignancy; where the treatment may be performed by ex vivo treatment of lymphocytes derived from the subject and subsequently infused back into the subject. Alternatively, the treatment may be performed by direct administration of the nanoparticles to the subject.

[0124] Solid tumor cancer: can be treated in a subject by in vivo administration of nanoparticles of the invention loaded with a cargo of one or more DNA constructs encoding receptors for specific targeting of tumor expressed antigens. For preclinical proof-of-principle, this can be modelled in mice by delivery of nanoparticles loaded with a cargo of a DNA construct encoding an OVA-specificT cell receptor 'OT1 TCR', for targeting an OVA-CT26 tumor in a mammalian subject suffering from a solid tumor cancer.

[0125] Autoimmune Disease: unwanted cells can be targeted in vivo by administration of nanoparticles of the invention that specifically delete unwanted cells, e.g. targeting CD19-expressing B cells by delivering a construct encoding a CD19 CAR. Alternatively, autoantigen-specific T cells can be targeted by such nanoparticles delivering a cargo comprising a foxp3-construct, since ectopic foxp3 expression has been shown to confer regulatory properties onto T cells, and thereby limit potential damage induced by these cells.

[0126] Heart Failure & vascular disease: can be treated in a mammalian subject suffering from heart failure or vascular disease by administration of nanoparticles of the invention loaded with cargo DNA molecules encoding a receptor such as a FAP-specific T cell receptor, 'FAP CAR'.

[0127] Administration of the nanoparticles of the invention to a mammalian subject can be by any route, including but not limited to intravenous, intranodal, intradermal, transdermal, subcutaneous, intramuscular, inhalation (e.g., via an aerosol), buccal (e.g., sub-lingual), topical (i.e., both skin and mucosal surfaces, including airway surfaces), intrathecal, intraarticular, intrapleural, intracerebral, intra-arterial, intraperitoneal, oral, intralymphatic, intranasal, rectal or vaginal administration, by perfusion through a regional catheter, or by direct intralesional injection.P3318PC00

[0128] In a preferred embodiment the mammalian subject in need of prophylactic or therapeutic treatment for a disease is a human.

[0129] IV. In a fourth embodiment, the invention provides a method of transfecting a mammalian cell ex vivo or in vitro with a population of the nanoparticles as defined in section I, comprising the step of contacting one or more mammalian cells with said population of the nanoparticles, whereby the one or more therapeutic agent(s) encapsulated by the nanoparticles are delivered to the one or more mammalian cells.

[0130] EXAMPLES

[0131] Example 1: Synthesis of Azido-PEG Dextran compounds

[0132] A: Synthetic steps leading to synthesis of Azido-PEG Dextran are set out below with reference to Figure 1 A.

[0133] A-l: Synthesis of Azido-PEG5k-NHS ester

[0134] Q

[0135]

[0136] Azido-PEG5k-NHS ester with the above structure is available from broadpharm.com / product / bp-40968.

[0137] A-2: Synthesis of aminated dextran

[0138] The dextran (6.0 g, 30.9 mmol, Mw 9000-11 000 g / mol, from Leuconostoc mesenteroides) was dissolved in 40 mL DMSO. After adding sodium cyanoborohydride and HDMA, the solution was stirred for 24 h at room temperature. The product was purified by dialysis of the solution against MQ water using a regenerated cellulose membrane with an MWCO of 3500 g / mol. The water was changed 5 times, and the sample was lyophilized to obtain a white powder.

[0139] A-3: Synthesis of Azido-PEG dextran

[0140] The above aminated dextran (2.0 g) was dissolved in 20 mL of DMSO, and azido-PEG-NHS polymer (4.0g, Sigma-Aldrich, USA) was added to the solution and kept stirring for 24 h. The solution was put into a dialysis tube (MWCO: 8,000 g / mol) and dialyzed against deionized water for 2 days. The product (see Figure 1A) was then lyophilized. A-4 : Synthesis of acetalated dextranP3318PC00

[0141] The azido-PEG dextran copolymer was dissolved in DMSO. Pyridinium-p-toluene sulfonate and 2-methoxypropene were added. The reaction was quenched with trimethylamine after 2h under an N2 atmosphere, yielding azido-PEG acetalated dextran (as exemplified in Figure 1A).

[0142] The product was then recovered through several repetitions of centrifugation (lOmin at 14800g followed by washing the pellet twice with mil HQ (MQ) water. Residual water was lyophilized over 3 days to obtain the final product.

[0143] The copolymer structure can be characterized by theXH NMR spectrometer (Varian 400 MHz NMR). The size of the polymer can be measured by gel permeation chromatography (GPC).

[0144] B: Alternatively, the synthesis steps leading to synthesis of an azido-PEG Dextran are set out below with reference to Figure 1 C, where the steps are analogue to the above-mentioned steps however, with the change of using HMDA instead of HDMA.

[0145] C: The synthetic route to Azido-PEG Dextran (compound 8C), as depicted in Figure IE, is described below.

[0146] C-l: Synthesis of Compound 8A (step 1 of Figure IE).

[0147] Dextran (8.42 g, 0.84 mmol, Mw 9000-11 000 g / mol, from Leuconostoc mesenteroides) was dissolved in 60 ml sodium acetate buffer (0.1 M, pH=4.91) in a 250 ml round bottom flask. 2-(Aminoxy) ethylamine dihydrochloride (12.6 mmol, 1,88 g) was added and the pH adjusted to 6.1 by the portion-wise addition of 2.875 ml 5 M NaOH. The solution was heated in a 75 °C aluminium heating block for 4 days. The solution was cooled on ice before being poured into a vigorously stirred mixture of 250 ml ethanol and 250 ml isopropanol, resulting in a sticky precipitate. The supernatant was decanted and the precipitate dissolved in 50 ml water. The aqueous solution was poured into 850 ml vigorously stirred acetone resulting in a sticky precipitate. The supernatant was decanted and the precipitate suspended in 100 ml acetone. The supernatant was decanted and the solids dried under vacuum. The solids were dissolved in 40 ml water, frozen and freeze-dried, yielding 6.82g (81%) of Compound 8A as a white solid.

[0148] 1H-NMR analysis in D2O was compatible with 95-100% end group functionalization. C-2: Synthesis of Compound 8B (step 2 of Figure IE).

[0149] Compound 8A (1608 mg, 0.16 mmol) and pyridinium toluenesulfonate (48 mg) were dissolved in anhydrous DMSO (32 ml) in a 100 ml round bottom flask and degassedP3318PC00

[0150] through two vacuum / nitrogen cycles. 2-methoxy propene (5.4 ml) was added and mixture stirred for 5 hours. Four 50 ml centrifuge tubes were each filled with 40 ml of a 0.1% aqueous solution of trimethylamine and 8 ml of reaction solution added to each tube, resulting in immediate precipitation. The precipitates were collected through centrifugation (3500G, 30 min, 4 °C), the supernatant was decanted and the solids resuspended in water before being combined in one tube. The precipitate was collected through centrifugation (3500G, 60 min, 4 °C), the supernatant decanted and the precipitate dried by blowing a stream of nitrogen over them for 1 hour before drying under vacuum. Extended centrifugation of the first supernatant followed by workup in the same manner yielded a second crop of product. The two crops were combined to yield 1.18 g (ca 80%) of Compound 8B as a white solid.

[0151] 1H-NMR. analysis in DMSO-d6 was compatible with acetalation of 80-100% hydroxyl groups.

[0152] C-3: Synthesis of Compound 8C (step 3 of Figure IE).

[0153] Compound 8B (381 mg) was dissolved in anhydrous DMSO (8 ml) in a 24 ml reaction vial. Azido-PEG5k-NHS (402 mg) was added, forming a clear colourless solution. The solution was stirred for 3 days before being diluted with 90 ml water, charged in a 7 kDa molecular weight cut-off dialysis tubing and dialyzed against 4000 ml water. The dialyzed solution was frozen and freeze dried, yielding 680 mg of Compound 8C as a white solid.

[0154] 1H-NMR. analysis in DMSO-d6 was consistent with >90% PEGylation.

[0155] D: The synthetic route to Azido-PEG Dextran (compound 12C), as depicted in Figure IF, is described below.

[0156] D-l: Synthesis of Compound 12B (step 1 of Figure IF).

[0157] Dextran (10.0 g, 1 mmol, Mw 9000-11 000 g / mol, from Leuconostoc mesenteroides ) was dissolved in anhydrous DMSO (148 ml) at 50 °C and degassed through four vacuum / nitrogen cycles before 2-(2-(2-azidoethoxy)ethoxy)ethyl lH-imidazole-1-carboxylate (Compound 12A, 11.5 g, 42.7 mmol) was added. The reaction mixture was stirred at 50 °C for 18 hours before it was cooled on ice. The solution was charged in a 3.5 kDa molecular weight cut-off dialysis tubing and dialyzed against 4000 ml water, and the water was changed 4 times. The dialyzed solution was freeze-dried, yielding 3.4 g of Compound 12B as a white powder.

[0158] 1H-NMR. analysis in DMS0-d6 was compatible the proposed structure.P3318PC00

[0159] D-2: Synthesis of Compound 12C (step 2 of Figure IF).

[0160] Compound 12B (1.04 g) and pyridinium toluenesulfonate (34 mg) were dissolved in anhydrous DMSO (12 ml) in a 50 ml round bottom flask and degassed through two vacuum / nitrogen cycles. 2-methoxy propene (3.3 ml) was added and mixture stirred for 3.5 hours. The reaction solution was diluted with dichloromethane (200 ml), and the organic solution washed with water (2x100 ml + 80 ml). The organic phase was dried over magnesium sulphate, filtered and concentrated under vacuum. The residue was dissolved in acetone (10 ml) and the solution filtered before being added to water (100 ml). The resulting suspension was frozen and freeze-dried, yielding 1.17 g of Compound 12C as a white powder.

[0161] 1H-NMR. analysis in DMSO-d6 was compatible with the proposed structure.

[0162] Example 2: Preparation of cargo-loaded amphiphilic dextran co-polymer: cationic lipid nanoparticles

[0163] 2.1 Component polymers of one embodiment of the nanoparticles of the invention -.

[0164] • Linear Azido-PEG AcDextran co-polymer was synthesized from azido-PEG5k- NHS ester and AcDextran, (as exemplified in examples 1, figure 1A and figure 1C). Azido-PEG5k-NHS ester is a PEG derivative containing an azide group and an NHS group. The hydrophilic azido-PEG portion increases the water solubility of the co-polymer.

[0165] • Cationic lipid: DC-Cholesterol is a cholesterol derivative and a cationic lipid with a head group and linker moiety, that is supplied by sigma aidrich (www.sigmaaldrich.com / DK / en / product / avanti / 700001p?srsltid=AfmBOor7Hxb wLHITEJCAdPd-uV3wAAAEQBttxgSpZMq9iWPqXV7qvGfc).

[0166] • A cargo of a nucleic acid therapeutic agent, using CleanCap® EGFP mRNA supplied by Tebubio (www.tebubio.com / dk-dkk / cleancap-egf -mma-5mou-l- mg / 563714B378.p) as a model nucleic acid.

[0167] • Optionally cathepsin responsive peptide is MC-Val-Cit-PAB-Gly-NHS ester is a cleavable ADC linker featuring a maleimide, a valine-citrulline (Val-Cit) dipeptide, and a para-aminobenzyl (PAB) spacer ligated to a glycine-NHS residue. The peptide can be purchased commercially from BroadPharm. (https: / / broadpharm.com / product / bp-40627)

[0168] 2.2 Assembly of one embodiment of nanoparticles of the invention-.P3318PC00

[0169] Assembly was performed according to the following steps:

[0170] (a) by providing the one or more therapeutic agent(s) in an aqueous solvent (e.g. PBS) and the amphiphilic azido-PEG-Acdextran copolymer (as exemplified in figure 1A or figure 1C) and the cationic lipid (e.g. DC-Cholesterol ) in a 1:1 ratio in a non-polar solvent (e.g. DCM),

[0171] (b) mixing the components of (a) to form a water-in-oil emulsion;

[0172] (c) mixing an volume of an aqueous solution of 3%PVA (a water-soluble synthetic polymer) with the water-in-oil emulsion of (b) to form a water-in-oil-in-water emulsion;

[0173] (d) mixing an equal volume of an aqueous solution of 0.3%PVA (a water-soluble synthetic polymer) with water-in-oil-in-water emulsion of (c) and

[0174] (e) evaporating the non-polar solvent from the water-in-oil-in-water emulsion of (d) to provide an aqueous solution of nanoparticles.

[0175] wherein a polar head group of said cationic lipid is orientated towards the core, and a hydrophilic portion of said copolymer is orientated towards the exterior surface of the nanoparticle.

[0176] In an alternative embodiment the amphiphilic azido-PEG-Acdextran copolymer of step (a) is a modified amphiphilic azido-PEG-Acdextran copolymer (as exemplified in example 2.2, and shown in figure IB or figure ID) comprising an enzyme-responsive peptide (e.g. cleavable peptide) incorporated in between the dextran polymer block and the PEG polymer block, as described in section I.

[0177] 2.3 Determining the dimensions of nanoparticles of the invention -.

[0178] The final diameter of the nanoparticles of the invention (comprising azido-PEG acetalated dextran di-block polymers and DC-Cholesterol) measured by nanoparticle tracking analysis (NTA) was found to be 227 nm. The structure of the nanoparticles (orientation of the copolymers and cationic lipid in the shell, and presence of the cargo-filled core) is determined by TEM images.

[0179] 2.3 Assembly of nanoparticles of the invention encapsulating a cargo of nucleic acid: Gene-encapsulating nanoparticles of the invention (e.g. loaded with a nucleic acid cargo of plasmid DNA or messenger RIMA) were assembled using a double emulsion (water / oil / water) method (figure 3). The respective stock nucleic acid solutions were prepared in nuclease-free distilled water. Amphiphilic azido-PEG-Acdextran di-blockP3318PC00

[0180] copolymer (20 mg) and DC cholesterol (10 mg) was dissolved in cold dichloromethane (DCM, 500 pL). The selected nucleic acid solution (100 pL, 0.2 mg / ml) was added, and the mixture subjected to sonication for 10 s on ice using a probe sonicator flat tip. Then the poly(vinyl alcohol) (ImL, 3% w / w in MQ water) was added to the primary emulsion solution and further sonicated for an additional 10 s on ice using the same settings. The resulting double emulsion was immediately poured into a second PVA solution (0.3% w / w in MQ water) and stirred for 3 h at room temperature for evaporating the DCM solvent. The nanoparticles were collected by centrifugation (10600 g, 8 min) and washed with PBS by sonication and vortexing. The washed particles were resuspended in PBS, lyophilized and stored at 4 degrees C until further use.

[0181] Example 3: Antibody conjugation to cargo-loaded amphiphilic azido-PEG-Acdextran di-block co-polymer:cationic lipid nanoparticles

[0182] Antibodies (e.g. anti-CD3) were conjugated to the cargo-loaded amphiphilic azido-PEG-Acdextran diblock co-polymer nanoparticles using click chemistry as follows, with reference to figure 4.

[0183] The anti-CD3 antibodies were conjugated to the nanoparticles of the invention using click chemistry. Purified anti-human CD3 antibody (OKT3, BioLegend) with a concentration of 0.5 mg / mL was buffer-exchanged by dialysis (Slide-A-Lyzer MINI Dialysis Devices, 10K) to remove free sodium azide. DBCO-Sulfo-NHS ester reagent was resuspended in DMSO at 10 mM concentration. The DBCO-Sulfo-NHS ester was added to the antibody at a molar ratio of 10:1 and incubated on ice for 2 h. The reaction was quenched with 75 mM Tris-HCI (pH 8) on ice for another 15 min. Non-reacted DBCO-Sulfo-NHS esters were removed by buffer-exchange to lx PBS, pH 7.4 using Zeba Spin Desalting columns, 7K MWCO. Next, the DBCO modified anti-CD3 (200 pl) were mixed with the nanoparticles (800 pl) for 24 h. The anti-CD3 modified nanoparticles were obtained by centrifugation (10600 g, 8 min, 3 times).

[0184] Example 4: Targeted in vitro cell transfection using cargo-loaded nanoparticles of the invention

[0185] Mammalian cells were transfected with CD-3 targeted cargo-loaded amphiphilic azido-PEG-Acdextran di-block co-polymer: cationic lipid nanoparticles as follows, with reference to figure 5 and 6.

[0186] 4.1 Samples and cell lines

[0187] Wild type (WT) Jurkat cells (TIB-152™) an immortalized leukemia cell line, and CD3 knockout Jurkat cells (TIB-152™), were purchased from American Type CultureP3318PC00

[0188] Collection, USA. Human primary T cells were isolated from PBMCs from healthy donors using EasySep™ Human T Cell Isolation Kit (STEMCELL Technologies).

[0189] CD-3 targeted nanoparticles, conjugated with anti-CD3 antibodies were prepared as described in example 3.

[0190] 4.2 Transfection of WT and CD3-knockout Jurkat cells

[0191] WT- and CD3-knockout Jurkat cells, were cultured in mammalian cell culture medium, RPMI-1640 with L-glutamine (ThermoFisher), that was supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin. Cells were plated at 100,000 cells per well in 96-well plates in the same cell media and were immediately treated with 0.5 to 8 ul of an aqueous solution of 4*107per ul CD-3 targeted nanoparticles, diluted in PBS at varying concentrations. The nanoparticles were loaded with the nucleic acid, CleanCap® EGFP mRNA supplied by Tebubio (www.tebubio.com / dk-dkk / cleancap-egfp-mma-5mou-l-mg / 563714 378.p), as a model for a therapeutic agent. After 48 h of incubation at 37°C in 35%CC>2, the cells were centrifuged at 500 g for 5 min, then the recovered cells were stained by live / dead NIR staining agent and suspended in 200 pl FACS buffer for analysis by flow cytometry.

[0192] 4.4 Transfection of human T cells

[0193] Isolated human primary T cells were seeded at 200,000 cells per well in 96-well plates in 200 pL of RPMI-1640 supplemented with 10% FBS, 1% penicillin-streptomycin and 20 lU / mL recombinant human IL-2 (Peprotech, USA). Nanoparticles of the invention, loaded with the nucleic acid anti-CD19-CAR mRNA as therapeutic agent, were either used directly for transfection, or were first pre-treated for 12 hours in human serum. The isolated T cells were treated with 2 to 8 ul of an aqueous solution of 4*107per ul CD-3 targeted nanoparticles (with or without pretreatment) that were diluted in PBS at varying concentrations. After 48 h of incubation, the cells were centrifuged at 500 g for 5 min and stained by live / dead NIR staining reagent for 20 min on ice. Finally, the cells were centrifuged at 500 g for 5 min, re-suspended in 200 pl FACS buffer, and analysed by flow cytometry.

[0194] Results: Figures 5 A, B show that the anti-CD3 conjugated nanoparticles were able to transfect Jurkat cells with efficiency up to 50%, based on expression of their GFP mRNA cargo, while transfection efficiency fell to about 15%, in CD3 knockdown Jurkat cells. This demonstrates that transfection by ligand-conjugated nanoparticles of the invention is cell specific and mediated by receptor-mediated endocytosis, in this case CD3. The transfection was shown to be nanoparticle dose dependent.

[0195] Figure 6A shows the surface expression of the CD19 CAR construct on CD3+ T cells analyzed by immunofluorescence microscopy. Figure 6B and C shows the expression ofP3318PC00

[0196] the CAR construct on the surface of T cells, by quantification of the frequency of CAR+ mCherry+ (co-encoded on the CAR mRNA construct) CD3+ T cells following incubation of the isolated T cells with CD3-targeting CD19 CAR-ligand-loaded nanoparticles. Preincubation of the nanoparticles in human serum for 12 hours had no impact on the transfection efficiency, demonstrating that the nanoparticles are stable in serum. Figure 6D demonstrates targeting of CD3-targeting nanoparticles selectively to CD3+ T cells also when administered to a PBMC sample containing a variety of immune cell types.

[0197] Example 5: Properties of cargo-loaded amphiphilic azido-PEG-Acdextran diblock co-polymer: cationic lipid nanoparticles

[0198] 5.1 Hydrodynamic radius and surface charge of cargo-loaded amphiphilic azido-PEG-Acdextran di-biock co-polymer:cationic lipid nanoparticles.

[0199] The average hydrodynamic radius of cargo-loaded nanoparticles and their antibody conjugated derivatives was measured using a nanoparticle tracking system (NanoSight NS300, Malvern Instrument). The zeta potential of the particles was determined using a Zeta Potential Analyzer (Malvern DLS Zetasizer). Cargo-loaded nanoparticles were found to have a diameter of 227 ± 56 nm and in zeta potential 43.37 ± 0.46 mV, while anti-CD3 antibody conjugation increased their diameter to 226 ± 52 nm, but reduced their zeta potential to -9.3 ± 1.5 mV due to the surface functionalization. 5.2 Cargo-loading capacity of amphiphilic azido-PEG-Acdextran di-biock copolymercationic lipid nanoparticles

[0200] Encapsulation of cargo nucleic acids (such as mRNA and DNA plasmid) in amphiphilic dextran di-biock: cationic lipid co-polymer nanoparticles includes the step of sonication of the nucleic acid to generate the primary and secondary emulsions used to form the nanoparticles. The loading capacity of the nanoparticles was investigated, since high ultrasonic power may fragment larger nucleic acid molecules (mRNA / plasmids); while insufficient ultrasonic power may compromise double emulsion formation.

[0201] Loading capacity: The encapsulation efficiency of mRNA in the nanoparticles was evaluated using a phase separation and fluorescence quantification method. In this procedure, 25 pL of nanoparticle dispersion (approximately 12 mg nanoparticles / mL) was combined with 200 pL of chloroform and 475 pL of Heparin-Detergent (HD) solution. The mixture was rotated end-over-end for 5 minutes to ensure the complete extraction of encapsulated mRNA into the aqueous phase. Phase separation was then achieved by centrifugation at 21,000 x g for 15 minutes at 4 °C. A 20 pL aliquot of the aqueous phase was carefully transferred to a fresh microcentrifuge tube for fluorescence analysis. The concentration of mRNA was determined using the Quant-iT™ RiboGreen™ RNA Assay Kit, with fluorescence readings recorded at excitation and emission wavelengths of 480 nm and 520 nm, respectively. The encapsulationP3318PC00

[0202] efficiency of the nanoparticles was calculated to be 37.1%, equivalent to 0.25 ug mRNA / mg nanoparticle.

[0203] 5.3 Surface chemistry impacts the transfection efficiency of amphiphilic azido -PEG-Acdextran di-biock co-poiymer:cationic lipid nanoparticles.

[0204] The effect of nanoparticle surface chemistry on transfection efficiency was analyzed by transfecting cells with cargo-loaded amphiphilic azido-PEG-Acdextran di-block copolymer: cationic lipid nanoparticles conjugated with targeting antibodies using click chemistry.

[0205] Without anti-CD3 antibody conjugation, no transfection in Jurkat cells was observed. While with anti-CD3 antibody attachment, a transfection efficiency up to 40% was achieved, indicating the surface conjugation with a targeting agent based on click chemistry was effective in increasing transfection.

[0206] 5.5 Targeting specificity of cargo-loaded amphiphilic azido-PEG-Acdextran di-biock copolymercationic lipid nanoparticles

[0207] Cargo-loaded amphiphilic azido-PEG-Acdextran di-block co-polymer: cationic lipid nanoparticles were conjugated with the targeting ligands: anti-CD3 antibody or anti-CD4 antibody or anti-CD5 antibody or anti-CD8 antibody. The antibodies were attached to nanoparticles of the invention loaded with CD19 CAR mRNA, which were incubated with primary T cells. The transfection efficiency of nanoparticles targeted with anti-CD3 antibody was about 6%; for those targeted with anti-CD4 antibody it was 0.6%; for those with anti-CD8 antibody it was about 0.4%; while those targeted with anti-CD5 antibody gave no transfection.

[0208] Example 6: In vivo cell transfection using dextran nanoparticles Figure 7 describes on a conceptual level how the gene-delivery nanoparticles will be used and will function in vivo. Briefly, once injected into a patient, the nanoparticles will interact with the target cells, which will induce receptor-mediated uptake of the nanoparticles into endosomes in the cytoplasm. After escaping the endosomes, the nanoparticles will release their DNA / RNA / protein payload into the cytoplasm. Protein and mRNA cargos will act directly in the cytoplasm, exerting their function or being translated into proteins, respectively, while a DNA cargo after localization to the nucleus, can be stably inserted into the genome and / or transcribed into mRNA for subsequent translation into protein in the cytoplasm. Finally, the mRNA / DNA-encoded product will be expressed on the surface of the targeted cell, e.g. in the form of a CAR or TCR. In vivo experiments, to confirm the nanoparticle functionality, will be performed in mouse models, either in all murine models allowing exploration of potential non-specific nanoparticle binding to other immune cell types, or in xeno-models obtained byP3318PC00

[0209] transferring human T cells and target tumor cells into immune-compromised NOG mice. Nanoparticles of the invention, loaded with a reporter protein (e.g GFP) or a fluorescent tag are used to assess targeting selectivity, or loaded with a mRNA- or DNA plasmid-encoded CD19-ligand CAR-construct are used to determine transfection efficiency and functionality. In both instances, the nanoparticles will be decorated with CD3-targeting ligands (i.e. targeting mouse or human CD3 depending on model).

[0210] In order to assess selectivity of nanoparticle targeting and transfection efficiency, nanoparticles loaded with a reporter protein or CD19-ligand CAR-encoding construct, will be injected intravenously into wild-type mice, or into NOG mice pre-inoculated with CD3-expressing Jurkat cells or human PBMCs (5-10 Mio cells / mouse, injected into the tail vein). At various time points after nanoparticle injection, nanoparticle targeting will be assessed by measuring the expression of the reporter / fluorescent tag or surface expression of the CAR construct on cells isolated from organs including, but not restricted to, peripheral blood, spleen and bone marrow. This analysis will include a broad range of immune cell types, including e.g. CD4 and CD8+ T cells, CD19+ B cells, CD16+ monocytes and CD56+ NK cells, to determine the targeting selectivity. The correlation between nanoparticle dose and expression of the delivered construct can then be determined.

[0211] To confirm the cytotoxic function of the cells transfected with the CAR construct, their capacity to kill a CD19-expressing tumor cell line will be tested in ex vivo co-culturing assays (Incucyte). Finally, to confirm the in vivo functionality of the engineered cells in a relevant disease model, human PBMCs will be adoptively transfer into NOG mice preinoculated with a CD19-expressing tumor cell line. Next, the mice will be treated with nanoparticles loaded with a CD19-ligand CAR-construct, and tumor growth and mouse survival assessed over time as readout of the capacity of the reprogrammed T cells to control the tumor.

[0212] Example 7: Expression cassettes encoding CAR sequences:

[0213] The following nucleic acid expression cassettes can be used as therapeutic cargos in the nanoparticles of the invention.

[0214] 7.1 Murine anti-FAP CAR sequence

[0215] The DNA sequence (SEQ ID No.: 1) in the sequence listing encodes a polypeptide having the following protein domains: mCD8 leader-aFAP (VH)-(G4S)4 linker-aFAP (VL)-mCD28 hinge / TM-mCD28 ICD-mCD3z (SEQ ID No.: 2).P3318PC00

[0216] The consecutive portions of the DNA sequence encoding each of said domains are reproduced below; wherein said consecutive portions when combined correspond to SEQ ID No.: 1 in the sequence listing: atggcgagcccgctgacccgctttctgagcctgaacctgctgctgctgggcgaaagcattattctgggcagcggcgaagcg encodes the mCD8 leader caggtgcagctgaaagaaagcggcggcctggtgcagccgggcggcagcctgaaactgagctgcgcggcgagcggcttt acctttagcagctatggcatgagctgggtgcgccagaccgcggataaacgcctggaactggtggcgaccaccaacaaca acggcggcgtgacctattatccggatagcgtgaaaggccgctttaccattagccgcgataacgcgaaaaacaccctgtatc tgcagatgagcagcctgcagagcgaagataccgcgatgtattattgcgcgcgctatggctattatgcgatggattattggg gccagggcattagcgtgaccgtgagcagc encodes aFAP (VH) ggaggcggaggatctggcggcggaggaagtggcggcggaggatctggcggcggaggaagc encodes the (648)4 linker.

[0217] gatgtgctgatgacccagaccccgctgtggctgccggtgagcctgggcgatcaggcgagcattagctgccgcagcagcca gagcattgtgcatagcaacggcaacacctatctggaatggtatctgggcaaaccgggccagagcccgaaactgctgattt ataaagtgagcaaccgctttagcggcgtgccggatcgctttagcggcagcggcagcggcaccgattttaccgtgaaaatta gccgcgtggaagcggaagatctgggcgtgtattattgctttggcggcagccatgtgccgtatacctttggcggcggcacca aactggaaattaaa encodes aFAP (VL).

[0218] attgaatttatgtatccgccgccgtatctggataacgaacgcagcaacggcaccattattcatattaaagaaaaacatctgt gccatacccagagcagcccgaaactgttttgggcgctggtggtggtggcgggcgtgctgttttgctatggcctgctggtgac cgtggcgctgtgcgtgatttggacc encodes mCD28 hinge / TM.

[0219] aatagtagaaggaacagactccttcaaagtgactacatgaacatgactccccggaggcctgggctcactcgaaagcctta ccagccctacgcccctgccagagactttgcagcgtaccgcccc encodes mCD28 ICD.

[0220] ctgagagcaaaattcagcaggagtgcagagactgctgccaacctgcaggaccccaaccagctctacaatgagctcaatct agggcgaagagaggaatatgacgtcttggagaagaagcgggctcgggatccagagatgggaggcaaacagcagagg aggaggaacccccaggaaggcgtatacaatgcactgcagaaagacaagatggcagaagcctacagtgagatcggcac aaaaggcgagaggcggagaggcaaggggcacgatggcctttaccagggtctcagcactgccaccaaggacacctatga tgccctgcatatgcagaccctggcccctcgc encodes mCD3z.

[0221] 7.2 Human anti-CD19 CAR sequence

[0222] The DNA sequence (SEQ ID No.: 3) in the sequence listing encodes a polypeptide having the following protein domains: hCD8 Leader-aCD19 (VH) -(G4S)4 linker-aCD19 (VL)-hCD8a hinge / TM-h4-lBB ICD-hCD3z (SEQ ID No.: 4).

[0223] The consecutive portions of the DNA sequence encoding each of said domains are reproduced below; wherein said consecutive portions when combined correspond to SEQ ID No.: 3 in the sequence listing: atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccgctcggccc - encodes hCD8 Leader;

[0224] Gaaattgtgatgacccagtcacccgccactcttagcctttcacccggtgagcgcgcaaccctgtcttgcagagcctcccaag acatctcaaaataccttaattggtatcaacagaagcccggacaggctcctcgccttctgatctaccacaccagccggctccaP3318PC00

[0225] ttctggaatccctgccaggttcagcggtagcggatctgggaccgactacaccctcactatcagctcactgcagccagagga cttcgctgtctatttctgtcagcaagggaacaccctgccctacacctttggacagggcaccaagctcgagattaaa -encodes aCD19 (VH);

[0226] ggaggcggaggatctggcggcggaggaagtggcggcggaggatctggcggcggaggaagc - encodes (648)4 linker;

[0227] caggtccaactccaagaaagcggaccgggtcttgtgaagccatcagaaactctttcactgacttgtactgtgagcggagtg tctctccccgattacggggtgtcttggatcagacagccaccggggaagggtctggaatggattggagtgatttggggctct gagactacttactaccaatcatccctcaagtcacgcgtcaccatctcaaaggacaactctaagaatcaggtgtcactgaaac tgtcatctgtgaccgcagccgacaccgccgtgtactattgcgctaagcattactattatggcgggagctacgcaatggatta ctggggacagggtactctggtcaccgtgtccagc - encodes aCD19 (VL);

[0228] accactaccccagcaccgaggccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggaggcatgta gacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttgggcccctctggctggtact tgcggggtcctgctgctttcactcgtgatcactctttactgt - encodes hCD8a hinge / TM;

[0229] aagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatgaggcctgtgcagactactcaagaggaggacgg ctgttcatgccggttcccagaggaggaggaaggcggctgcgaactg - encodes h4-lBB ICD;

[0230] cgcgtgaaattcagccgcagcgcagatgctccagcctaccaacaggggcagaaccagctctacaacgaactcaatcttgg tcggagagaggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaagccgcgcagaaa gaatccccaagagggcctgtacaacgagctccaaaaggataagatggcagaagcctatagcgagattggtatgaaagg ggaacgcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgctct tcacatgcaggccctgccgcctcgg - encodes hCD3z.

[0231] Example 8: Synthesis of nanoparticles from using Compound 8C (compound of example 1C)

[0232] 8.1 Synthesis of nanoparticles using Compound 8C, DC-choiesteroi, and mCherry mRNA.

[0233] Compound 8C (20 mg) and DC-cholesterol hydrochloride (10 mg) were dissolved in dichloromethane (516 pl) in a 8 ml glass vial. The dichlormethane solution was mixed with 100 pl of a 1 mg / ml solution of mCherry mRNA in PBS through vortexing. The mixture was sonicated on ice using a probe sonicator for 2 times 10 seconds. A 3% aqueous solution of PVA (1 ml, mw 30-70 kDa, 89-90% hydrolyzed) was added and the mixture briefly vortexed before being sonicated on ice using a probe sonicator for 2 times 10 seconds. A 0.3% aqueous solution of PVA (5 ml, mw 30-70 kDa, 89-90% hydrolyzed) and a stir bar was added before the mixture was left stirring open to air overnight. The formed nanoparticle solution was concentrated to ca 2.5 ml on a 1000 kDa molecular weight cut-off spin filter, diluted to 20 ml with PBS and concentrated to 4 ml, again diluted to 20 ml with PBS and concentrated to ca 1 ml of a solution of nanoparticles.

[0234] Hydrodynamic diameter (DLS, intensity weighted diameter of the main peak): 162 nm.P3318PC00

[0235] 8.2 Conjugation of anti-CD3 antibody to nanoparticles according to Example 8.1 A portion of anti-CD3 antibody solution (50.4 pl of a 9.92 mg / ml stock solution) was mixed with 950 pl PBS in an Eppendorf-tube before DBCO-sulfo-NHS (16.8 ul of a lOmM stock solution in DMSO) was added. The mixture was briefly vortexed and incubated at room temperature for an hour before tris buffer (90 pl, 1 M) was added and the mixture incubated for another 15 minutes. The solution was passed through a Zebaspin desalting column (2 mL - 7 kDa molecular weight cut-off), yielding a solution of DBCO-conjugated antibody.

[0236] Nanoparticles according to Example 8.1 (50 pl) were mixed with the solution of DBCO-conjugated antibody (100 pl) and incubated at 4 °C for 24 hours, yielding a solution of nanoparticles with anti-CD3 antibody conjugated to the outer part.

[0237] 8.3 Synthesis of nanoparticles from Compound 8C, DC-cholesterol, DOTAP, and mCherry mRNA.

[0238] Nanoparticles were synthesized according to Example 8.1 but where the DC-cholesterol hydrochloride was substituted with 5 mg of DC-cholesterol hydrochloride and 5 mg DOTAP chloride.

[0239] The hydrodynamic diameter (DLS, intensity weighted diameter of the main peak) of the synthesized nanoparticles was determined to be: 112 nm

[0240] 8.4 Conjugation of anti-CD3 antibody to nanoparticles according to Example 8.3.

[0241] Nanoparticles according to Example 8.3 were conjugated with anti-CD3 antibody by the same method as in Example 8.2.

[0242] 8.5 Synthesis of nanoparticles from Compound 8C, DOTAP, and mCherry mRNA.

[0243] Nanoparticles were synthesized according to Example 8.1, but where the DC-cholesterol hydrochloride was substituted with 10 mg DOTAP chloride.

[0244] The hydrodynamic diameter (DLS, intensity weighted diameter of the main peak) of the synthesized nanoparticles was determined to be: 102 nm

[0245] 8.6 Conjugation of anti-CD3 antibody to nanoparticles according to Example 8.5.

[0246] Nanoparticles according to Example 8.5 were conjugated with anti-CD3 antibody by the same method as in Example 8.2.

[0247] 8.7 Synthesis of nanoparticles from Compound 8C, DC-cholesterol, and luciferase mRNA.

[0248] Nanoparticles were synthesized according to Example 8.1 but where the mCherry mRNA was substituted with luciferase mRNA.P3318PC00

[0249] The hydrodynamic diameter (DLS, intensity weighted diameter of the main peak) of the synthesized nanoparticles was determined to be: 154 nm.

[0250] Example 9: In vitro transfection of Jurkat cells using nanoparticles according to Example 8

[0251] A 96 well plate was seeded with Jurkat cells 100 000 cells / well (1 000 000 cells per ml in R10 medium). Wells were treated with 10 ul of nanoparticles according to Examples 8.2, 8.4, and 8.6 before addition of 50 ul R10 medium. The cells were incubated at 37 °C for 24 hours and analyzed for mCherry expression using flow cytometry.

[0252] Flow cytometry analysis of Jurkat cells following the in vitro transfection with nanoparticles prepared according to Examples 8.2, 8.4, and 8.6 (figure 8) showed detectable levels of mCherry expression in 6 %, 4%, and 2% of live cells, respectively.

[0253] Example 10: In vivo transfection using nanoparticles prepared according to Example 8.7

[0254] A female wildtype balb / C mouse was injected intravenously with 200 ul of nanoparticles prepared according to Example 8.7, via the tail vein. After 24 hours the mouse was injected intraperitoneally with luciferin. After 15 minutes the mouse was imaged by IVIS before being sacrificed. Lung, spleen and liver were dissected and imaged as illustrated in Figure 9.

[0255] Bioluminescence images of dissected organs of mice (figure 9) showed strong bioluminescence in the lungs, but no detectable signal in liver or spleen, indicating that the nanoparticles do not accumulate in the liver. Dissected lung had a bioluminescence intensity 159 times stronger than liver and 94 times stronger than spleen.

[0256] Example 11: Synthesis of nanoparticles from using Compound 12C.

[0257] 11.1 Synthesis of nanoparticles from using Compound 12C, DC-cholesterol, and luciferase-mCherry mRNA.

[0258] Compound 12C (20 mg) and DC-cholesterol hydrochloride (10 mg) were dissolved in dichloromethane (516 pl) in a 8 ml glass vial. The dichlormethane solution was mixed with 100 pl of a 1 mg / ml solution of luciferase-mCherry mRNA in PBS through vortexing. The mixture was sonicated on ice using a probe sonicator for 2 times 10 seconds. A 3% aqueous solution of PVA (1 ml, mw 30-70 kDa, 89-90% hydrolyzed) was added and the mixture briefly vortexed before being sonicated on ice using a probe sonicator for 2 times 10 seconds. A 0.3% aqueous solution of PVA (5 ml, mwP3318PC00

[0259] 30-70 kDa, 89-90% hydrolyzed) and a stir bar was added before the mixture was left stirring open to air for 44 hours. The nanoparticles were isolated through centrifugation (10600G, 10 min), the supernant pipetted off and the nanoparticles resuspended in 1 ml PBS using a probe sonicator for 10 seconds. The centrifugation-resuspension cycle repeated twice for a total of three resuspensions.

[0260] The hydrodynamic diameter (DLS, intensity weighted diameter of the main peak) of the synthesized nanoparticles was determined to be: 312 nm.

[0261] 11.2 Synthesis of nanoparticles from using Compound 12C, 98N12-5, and GFP mRNA. Nanoparticles were synthesized according to Example 11.1 but using 12.75 mg of Compound 12C, substituting the DC-cholesterol hydrochloride with 2.25 mg of 98N12-5 lipid (Nl,N16-didodecyl-4,7,13-tris(3-(dodecylamino)-3-oxopropyl)-4,7,10,13-tetraazahexadecanediamide, Nl,N16-didodecyl-4,7,13-tris(3-(dodecylamino)-3-oxopropyl)-4,7,10,13-tetraazahexadecanediamide, CAS number 917572-74-8), and substituting the luciferase-mCherry mRNA with GFP RNA.

[0262] 11.3 Conjugation of anti-CD3 antibody to nanoparticles according to Example 11.2 Nanoparticles according to Example 11.2 were conjugated with anti-CD3 antibody by the same method as in Example 8.2.

[0263] 11.4. In vitro transfection of Jurkat cells using nanoparticles according to Example 11.3.

[0264] Jurkat cells were transfected using nanoparticles according to Example 11.3 using the same methodology as in Example 9. Flow cytometry analysis of the Jurkat cells following the in vitro transfection with nanoparticles prepared according to Example 11.3 showed GFP expression in 43 % of live cells as illustrated in Figure 10.

[0265] In some embodiments the invention provides an aqueous-dispersible nanoparticle for encapsulating and delivering one or more molecule(s) or therapeutic agent(s) to a mammalian cell or tissue, wherein the nanoparticle comprises a) a hydrophilic core comprising the one of more molecule(s) or therapeutic agents; and b) a shell comprising molecules of an amphiphilic copolymer and a cationic lipid, wherein the nanoparticle is formed by water-in-oil-in-water emulsification, wherein the copolymer is composed of a hydrophobic dextran polymer covalently linked to a hydrophilic polymer, wherein a polar head group of said cationic lipid is orientated towards the core, and a hydrophilic portion of said copolymer is orientated towards the exterior surface of the nanoparticle.P3318PC00

[0266] In such embodiments of the nanoparticle, the amphiphilic copolymer comprises an azido-PEG polymer covalently linked to an acetalated dextran polymer at a non-reducing end or at a side chain of said acetalated dextran polymer.

[0267] In such embodiments the nanoparticle of said cationic lipid is selected from among cholesteryl 3p-N-(dimethylaminoethyl)carbamate hydrochloride; 1,2-di-O-octadecenyl-3-trimethylammonium-propane; 8-[(2-hydroxyethyl)[8-(nonyloxy)-8-oxooctyl]amino]-octanoic acid; 1 -octylnonyl ester; l,2-dioleoyl-3-trimethylammonium-propane; and Nl,N16-didodecyl-4,7,13-tris(3-(dodecylamino)-3-oxopropyl)-4,7,10,13-tetraazahexadecanediamide.

[0268] In such embodiments the nanoparticle further comprises c) a targeting agent linked to the hydrophilic portion of said copolymer.

[0269] In such embodiments of the nanoparticle, said cell-specific targeting agent is conjugated to one or more azido group of said azido-PEG polymers.

[0270] In such embodiments of the nanoparticle, the azido-PEG polymer is co-valently linked to the non-reducing end or side chain of the acetalated dextran polymer by an enzyme-cleavable peptide linker.

[0271] In such embodiments of the nanoparticle at least one of said molecule(s) or therapeutic agents is selected from among a nucleic acid molecule; a peptide, a polypeptide; and a small molecule; or any combination thereof.

[0272] In such embodiments of the nanoparticle at least one of said molecule(s) or therapeutic agents is a nucleic acid molecule, selected from among a DNA molecule, a DNA plasmid, an RNA molecule, a mRNA molecule, an siRNA molecule.

[0273] In some embodiments of the invention a pharmaceutical composition for use as a medicament, comprising a population of the nanoparticles wherein the hydrophilic core comprises the one of more therapeutic agents.

[0274] In such embodiments of the pharmaceutical composition for use as a medicament the medicament is for treatment of cancer or an immune-related disease, and wherein the nanoparticles comprise a targeting agent for delivery of the therapeutic agent(s) to a target immune cell having a cognate receptor for the targeting agent.P3318PC00

[0275] In such embodiments of the pharmaceutical composition for use as a medicament the target immune cell is a T cell and the targeting agent is an ligand to a cell-surface receptor of said T cell.

[0276] In such embodiments of the pharmaceutical composition for use as a medicament the composition is for in vivo administration.

[0277] In some embodiments of the invention a method for producing a population of nanoparticles comprises D) providing one or more aqueous solutions of one or more molecules or therapeutic agent(s) and providing a non-polar solution comprising an amphiphilic copolymer and a cationic lipid; E) mixing the aqueous solution(s) and the non-polar solution of (a) to form a water-in-oil emulsion; F) mixing an aqueous solution of a water-soluble synthetic polymer with the water-in-oil emulsion of (b) to form a water-in-oil-in-water emulsion; G) mixing an equal volume of a further aqueous solution of a water-soluble synthetic polymer with the water-in-oil-in-water emulsion of (c) and H) evaporating the non-polar solvent from the water-in-oil-in-water emulsion of (d) to provide an aqueous solution of nanoparticles; and optionally I) linking said nanoparticles of (e) with a cell-specific targeting ligand wherein the copolymer is composed of a hydrophobic dextran polymer covalently linked to a hydrophilic polymer, and wherein a polar head group of said cationic lipid is orientated towards a core of the nanoparticle, and a hydrophilic portion of said copolymer is orientated towards the exterior surface of the nanoparticle.

[0278] In such embodiments of a method for producing a population of nanoparticles the solution of a water-soluble synthetic polymer in step (c) is about 3% polyvinyl alcohol, and in step (d) is about 0.3% polyvinyl alcohol.

[0279] In such embodiments of a method for producing a population of nanoparticles may further comprising the step of: E) conjugating a targeting agent to a hydrophilic portion of said amphiphilic copolymer.

Claims

1. 33P3318PC00Claims:

1. An aqueous-dispersible nanoparticle for encapsulating and delivering one or more molecule(s) or therapeutic agent(s) to a mammalian cell or tissue, wherein the nanoparticle comprises:(a) a hydrophilic core comprising the one of more molecule(s) or therapeutic agents; and(b) a shell comprising molecules of an amphiphilic copolymer and a cationic lipid,wherein the nanoparticle is formed by water-in-oil-in-water emulsification, wherein the copolymer is composed of a hydrophobic dextran polymer covalently linked to a hydrophilic polymer,wherein a polar head group of said cationic lipid is orientated towards the core, and a hydrophilic portion of said copolymer is orientated towards the exterior surface of the nanoparticle;wherein the nanoparticle further comprises a targeting agent linked to the hydrophilic portion of said copolymer.

2. The nanoparticle of claim 1,wherein the amphiphilic copolymer comprises an azido-PEG polymer covalently linked to an acetalated dextran polymer.

3. The nanoparticle of claim 1 or 2,wherein the amphiphilic copolymer comprises an azido-PEG polymer covalently linked to an acetalated dextran polymer at a non-reducing or a reducing end or at a side chain of said acetalated dextran polymer.

4. The nanoparticle of any one of claims 1 - 3,wherein said cationic lipid is selected from among cholesteryl 3 -N- (dimethylaminoethyl)carbamate hydrochloride; l,2-di-O-octadecenyl-3- trimethylammonium-propane; 8-[(2-hydroxyethyl)[8-(nonyloxy)-8- oxooctyl]amino]-octanoic acid; 1-octylnonyl ester; l,2-dioleoyl-3- trimethylammonium-propane; and Nl,N16-didodecyl-4,7,13-tris(3- (dodecylamino)-3-oxopropyl)-4,7,10,13-tetraazahexadecanediamide.

5. The nanoparticle of any one of claims 2 - 4,wherein said cell-specific targeting agent is conjugated to one or more azido group of said azido-PEG polymers.34P3318PC006. The nanoparticle of any one of claims 2 - 5,wherein the azido-PEG polymer is co-valently linked to the non-reducing or the reducing end or side chain of the acetalated dextran polymer by an enzyme- cleavable peptide linker.

7. The nanoparticle of any one of claims 1 - 6,wherein at least one of said molecule(s) or therapeutic agent(s) is selected from among a nucleic acid molecule; a peptide, a polypeptide; and a small molecule; or any combination thereof.

8. The nanoparticle of any one of claims 1 - 6,wherein at least one of said molecule(s) or therapeutic agent(s) is a nucleic acid molecule, selected from among a DNA molecule, a DNA plasmid, an RIMA molecule, an mRNA molecule, and an siRNA molecule.

9. A pharmaceutical composition for use as a medicament, comprising a population of the nanoparticles of any one of claims 1 - 8, wherein the hydrophilic core comprises the one of more therapeutic agents.

10. The pharmaceutical composition for use as a medicament according to claim 9, wherein said medicament is for treatment of cancer or an immune-related disease, andwherein the nanoparticles comprise a targeting agent for delivery of the therapeutic agent(s) to a target immune cell having a cognate receptor for the targeting agent.

11. The pharmaceutical composition for use as a medicament according to claim 10, wherein the target immune cell is a T cell and the targeting agent is an ligand to a cell-surface receptor of said T cell.

12. The pharmaceutical composition for use as a medicament according to any one of claims 9 - 11, wherein the composition is for in vivo administration.

13. A method for producing a population of nanoparticles according to any one of claims 1 - 8 comprising:(a) providing one or more aqueous solutions of one or more molecule(s) or therapeutic agent(s) and providing a non-polar solution comprising an amphiphilic copolymer and a cationic lipid;P3318PC00(b) mixing the aqueous solution(s) and the non-polar solution of (a) to form a water-in-oil emulsion;(c) mixing an aqueous solution of a water-soluble synthetic polymer with the water-in-oil emulsion of (b) to form a water-in-oil-in-water emulsion;(d) optionally mixing a volume of a further aqueous solution of a water- soluble synthetic polymer with the water-in-oil-in-water emulsion of (c) and(e) evaporating the non-polar solvent from the water-in-oil-in-water emulsion of (c) or (d) to provide an aqueous solution of nanoparticles; and(f) linking said nanoparticles of (e) with a cell-specific targeting agent wherein the copolymer is composed of a hydrophobic dextran polymer covalently linked to a hydrophilic polymer, andwherein a polar head group of said cationic lipid is orientated towards a core of the nanoparticle, and a hydrophilic portion of said copolymer is orientated towards the exterior surface of the nanoparticle, wherein said linking in step (f) comprises conjugating said targeting agent to a hydrophilic portion of said amphiphilic copolymer.

14. The method for producing a population of nanoparticles of claim 13, wherein the solution of a water-soluble synthetic polymer in step (c) is about 3% polyvinyl alcohol, and in step (d) is about 0.3% polyvinyl alcohol.